MEI Pharma Inc. [MEIP] Stock trading around $2.79 per share: What’s Next?

MEI Pharma Inc. [NASDAQ: MEIP] closed the trading session at $2.79 on 08/11/20. The day’s price range saw the stock hit a low of $2.62, while the highest price level was $2.89. The company report on August 11, 2020 that SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.

Los Angeles, California–(Newsfile Corp. – August 11, 2020) – The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. (“MEI Pharma” or “the Company”) (NASDAQ: MEIP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between August 2, 2017 and July 1, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before October 9, 2020.

The stocks have a year to date performance of 12.50 percent and weekly performance of 1.82 percent. The stock has been moved at 16.74 percent over the last six months. The stock has performed -14.94 percent around the most recent 30 days and changed -1.41 percent over the most recent 3-months.

If compared to the average trading volume of 1.89M shares, MEIP reached to a volume of 1447428 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about MEI Pharma Inc. [MEIP]:

SunTrust have made an estimate for MEI Pharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 29, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 20, 2018, representing the official price target for MEI Pharma Inc. stock. On July 27, 2018, analysts increased their price target for MEIP shares from 2.50 to 7.

The Average True Range (ATR) for MEI Pharma Inc. is set at 0.20, with the Price to Sales ratio for MEIP stock in the period of the last 12 months amounting to 64.30. The Price to Book ratio for the last quarter was 3.99, with the Price to Cash per share for the same quarter was set at 0.89.

MEIP stock trade performance evaluation

MEI Pharma Inc. [MEIP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.82. With this latest performance, MEIP shares dropped by -14.94% in over the last four-week period, additionally plugging by 16.74% over the last 6 months – not to mention a rise of 82.35% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MEIP stock in for the last two-week period is set at 41.61, with the RSI for the last a single of trading hit 41.07, and the three-weeks RSI is set at 41.79 for MEI Pharma Inc. [MEIP]. The present Moving Average for the last 50 days of trading for this stock 3.48, while it was recorded at 2.76 for the last single week of trading, and 2.47 for the last 200 days.

MEI Pharma Inc. [MEIP]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and MEI Pharma Inc. [MEIP] shares currently have an operating margin of -940.90 and a Gross Margin at +13.27. MEI Pharma Inc.’s Net Margin is presently recorded at -342.20.

Return on Total Capital for MEIP is now -94.00, given the latest momentum, and Return on Invested Capital for the company is -34.19. Return on Equity for this stock declined to -34.19, with Return on Assets sitting at -17.96.

Reflecting on the efficiency of the workforce at the company, MEI Pharma Inc. [MEIP] managed to generate an average of -$420,475 per employee. Receivables Turnover for the company is 1.65 with a Total Asset Turnover recorded at a value of 0.05.MEI Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.

Earnings per share (EPS) analysis for MEI Pharma Inc. [MEIP] stock

With the latest financial reports released by the company, MEI Pharma Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.2/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MEIP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for MEI Pharma Inc. go to -0.10%.

MEI Pharma Inc. [MEIP]: Insider Ownership positions

There are presently around $200 million, or 70.20% of MEIP stock, in the hands of institutional investors. The top three institutional holders of MEIP stocks are: VIVO CAPITAL, LLC with ownership of 9,784,422, which is approximately -3.738% of the company’s market cap and around 0.50% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, holding 8,533,072 shares of the stock with an approximate value of $23.81 million in MEIP stocks shares; and MPM ONCOLOGY IMPACT MANAGEMENT LP, currently with $17.44 million in MEIP stock with ownership of nearly 0% of the company’s market capitalization.

54 institutional holders increased their position in MEI Pharma Inc. [NASDAQ:MEIP] by around 6,974,976 shares. Additionally, 29 investors decreased positions by around 5,323,259 shares, while 16 investors held positions by with 59,447,456 shares. The mentioned changes placed institutional holdings at 71,745,691 shares, according to the latest SEC report filing. MEIP stock had 14 new institutional investments in for a total of 1,952,121 shares, while 10 institutional investors sold positions of 2,314,937 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam